Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer

Fig. 6

m6A modification patterns in the role of anti-PD-1/L1 immunotherapy. a Survival analyses for low (89 cases) and high (169 cases) m6Ascore patient groups in the anti-PD-L1 immunotherapy cohort using Kaplan-Meier curves (IMvigor210 cohort; HR, 1.73(1.20–2.48); P = 0.002, Log-rank test). b The proportion of patients with response to PD-L1 blockade immunotherapy in low or high m6Ascore groups. SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response. Responser/Nonresponer: 41%/58% in the low m6Ascore groups and 20%/80% in the high m6Ascore groups. c Distribution of m6Ascore in distinct anti-PD-L1 clinical response groups. d Survival analyses for low and high m6Ascore patient groups in the anti-PD1 immunotherapy cohort using Kaplan-Meier curves (GSE78220 cohort; HR, 4.58(1.23–17.10); P = 0.013, Log-rank test). e The proportion of patients with response to PD-1 blockade immunotherapy in low or high m6Ascore groups. Responser/Nonresponer: 71%/29% in the low m6Ascore groups and 25%/75% in the high m6Ascore groups. f The correlation of m6Ascore with clinical response to anti-PD-1 immunotherapy. Pt, patients. PD, blue; PR, purple; CR, red. g Differences in m6Ascore among distinct anti-PD-1 clinical response groups. h Differences in PD-L1 expression between low and high m6Ascore groups (p < 0.0001, Wilcoxon test). i Differences in stroma-activated pathways and abundance of regulatory T cells (considered as immune suppression) between low m6Ascore and high m6Ascore groups in anti-PD-L1 immunotherpy cohort (*P < 0.05; **P < 0.01; ***P < 0.001). j Survival analyses for patients receiving anti-PD-L1 immunotherapy stratified by both m6Ascore and neoantigen burden using Kaplan-Meier curves. H, high; L, Low; NEO, neoantigen burden (P < 0.0001, Log-rank test). k The predictive value of the quantification of m6A modification patterns in patients treated with anti-PD-1/L1 immunotherapy (AUC, 0.768). l Differences in m6Ascore among distinct tumor immune phenotypes in IMvigor210 cohort. The lines in the boxes represented median value (p = 0.015, Kruskal-Wallis test)

Back to article page